ES2501592T3 - Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña - Google Patents

Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña Download PDF

Info

Publication number
ES2501592T3
ES2501592T3 ES10014318.9T ES10014318T ES2501592T3 ES 2501592 T3 ES2501592 T3 ES 2501592T3 ES 10014318 T ES10014318 T ES 10014318T ES 2501592 T3 ES2501592 T3 ES 2501592T3
Authority
ES
Spain
Prior art keywords
treatment
stereoisomer
butylphenol
nausea
vomiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10014318.9T
Other languages
English (en)
Inventor
Thomas E. Jenkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOWOOD HEALTHCARE LLC
Original Assignee
SOWOOD HEALTHCARE LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOWOOD HEALTHCARE LLC filed Critical SOWOOD HEALTHCARE LLC
Application granted granted Critical
Publication of ES2501592T3 publication Critical patent/ES2501592T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06—Alkylated phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C07C37/0555—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group being esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

Un estereoisómero (-) de fórmula (I):**Fórmula** en donde X es H o F, o una sal farmacéuticamente aceptable del mismo, para: fomentar un efecto antiemético en un animal; tratar náuseas o vómitos; o tratar una migraña en un animal.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20

Claims (1)

  1. imagen1
ES10014318.9T 2007-05-09 2008-05-08 Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña Active ES2501592T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92842907P 2007-05-09 2007-05-09
US92832707P 2007-05-09 2007-05-09
US92829607P 2007-05-09 2007-05-09
US928429P 2007-05-09
US928327P 2007-05-09
US928296P 2007-05-09

Publications (1)

Publication Number Publication Date
ES2501592T3 true ES2501592T3 (es) 2014-10-02

Family

ID=39798084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10014318.9T Active ES2501592T3 (es) 2007-05-09 2008-05-08 Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña

Country Status (23)

Country Link
US (4) US8071818B2 (es)
EP (4) EP2292577A1 (es)
JP (1) JP5651009B2 (es)
KR (1) KR20100017436A (es)
CN (1) CN101715437B (es)
AT (1) ATE487685T1 (es)
AU (1) AU2008251482C1 (es)
BR (1) BRPI0811220A2 (es)
CA (1) CA2685570A1 (es)
DE (1) DE602008003431D1 (es)
DK (2) DK2301908T3 (es)
ES (1) ES2501592T3 (es)
HK (2) HK1138829A1 (es)
HR (1) HRP20140896T1 (es)
IL (1) IL201795A0 (es)
MX (1) MX2009012124A (es)
NZ (1) NZ580752A (es)
PL (2) PL2146946T3 (es)
PT (1) PT2146946E (es)
RU (1) RU2470908C2 (es)
SI (1) SI2301908T1 (es)
WO (1) WO2008141097A2 (es)
ZA (1) ZA201007603B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5651009B2 (ja) 2007-05-09 2015-01-07 ソウッド ヘルスケア エルエルシー 治療用化合物
WO2012017950A1 (ja) * 2010-08-03 2012-02-09 学校法人 久留米大学 実験用小動物の脳波測定用電極装置及び脳波測定方法
CN102731265B (zh) * 2012-06-12 2014-12-10 四川百利药业有限责任公司 一种高纯度丙泊酚的制备方法
WO2017205632A1 (en) * 2016-05-27 2017-11-30 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
RU2635532C1 (ru) * 2016-09-06 2017-11-13 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики ажитационного синдрома у детей с онкологической патологией
CN115708819A (zh) * 2022-11-24 2023-02-24 中国科学院深圳先进技术研究院 丙泊酚的抗焦虑制药用途及抗焦虑药物制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US237213A (en) 1881-02-01 William j
US2747982A (en) * 1955-05-11 1956-05-29 Dow Chemical Co Method and composition for the control of the growth of vegetation
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
SU1525139A1 (ru) * 1987-11-10 1989-11-30 Куйбышевский политехнический институт им.В.В.Куйбышева Способ получени о-втор-бутилфенола
ES2087019B1 (es) * 1994-02-08 1997-03-16 Bobel246 S L Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
US5731355A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
WO2000048572A1 (en) 1999-02-18 2000-08-24 Supergen, Inc Phosphocholine linked prodrug derivatives
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6362234B1 (en) 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
WO2002028411A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN
DE60232271D1 (de) 2001-12-28 2009-06-18 Eisai Corp North America Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
EP1492544A4 (en) 2002-04-08 2005-10-12 Guilford Pharm Inc PHARMACEUTICAL COMPOSITIONS CONTAINING PROPOFOL-BASED WATER-SOLUBLE PRODRUGS AND METHODS OF ADMINISTRATION THEREOF
DE20215415U1 (de) 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
ZA200504940B (en) 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
WO2005023204A2 (en) 2003-09-09 2005-03-17 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US20070043121A1 (en) * 2003-09-29 2007-02-22 Brown Milton L Discovery of novel soluble crystalline anesthetics
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
US20080214508A1 (en) 2004-09-17 2008-09-04 Mgi Gp, Inc. Methods of Administering Water-Soluble Prodrugs of Propofol
JP2008525501A (ja) 2004-12-23 2008-07-17 ゼノポート，インコーポレイティド セリンアミノ酸誘導のプロポフォールのプロドラッグ、その使用及び結晶体
DE102005033496A1 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel
JP5537033B2 (ja) * 2005-12-19 2014-07-02 ザ ユニヴァーシティー オブ リヴァプール 無痛覚
US7535698B2 (en) 2006-03-07 2009-05-19 Panasonic Corporation Case, portable information equipment using the same and manufacturing method of the case
US7731356B1 (en) * 2006-07-24 2010-06-08 Daniel Ayers Gilbert Hanging eyeglasses
AU2008251484A1 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Therapeutic compounds
JP5651009B2 (ja) 2007-05-09 2015-01-07 ソウッド ヘルスケア エルエルシー 治療用化合物

Also Published As

Publication number Publication date
JP5651009B2 (ja) 2015-01-07
EP2301908A1 (en) 2011-03-30
EP2810927A1 (en) 2014-12-10
DK2301908T3 (da) 2014-09-15
US8575400B2 (en) 2013-11-05
US8871815B2 (en) 2014-10-28
SI2301908T1 (sl) 2014-10-30
KR20100017436A (ko) 2010-02-16
AU2008251482C1 (en) 2014-04-03
US8071818B2 (en) 2011-12-06
DK2146946T3 (da) 2011-02-14
US20120035271A1 (en) 2012-02-09
ATE487685T1 (de) 2010-11-15
US20100292346A1 (en) 2010-11-18
US20130059919A1 (en) 2013-03-07
EP2146946B1 (en) 2010-11-10
WO2008141097A2 (en) 2008-11-20
WO2008141097A3 (en) 2008-12-31
EP2301908B8 (en) 2014-09-03
AU2008251482A1 (en) 2008-11-20
US8242315B2 (en) 2012-08-14
DE602008003431D1 (de) 2010-12-23
EP2292577A1 (en) 2011-03-09
HK1138829A1 (en) 2010-09-03
PL2301908T3 (pl) 2015-02-27
PL2146946T3 (pl) 2011-04-29
EP2301908B1 (en) 2014-06-25
CN101715437B (zh) 2013-06-12
BRPI0811220A2 (pt) 2014-10-29
HK1156019A1 (en) 2012-06-01
MX2009012124A (es) 2010-02-18
RU2470908C2 (ru) 2012-12-27
WO2008141097A9 (en) 2009-04-02
RU2009145537A (ru) 2011-06-20
HRP20140896T1 (hr) 2015-01-02
US20140206773A1 (en) 2014-07-24
JP2010526826A (ja) 2010-08-05
ZA201007603B (en) 2012-08-29
AU2008251482B2 (en) 2013-09-26
NZ580752A (en) 2012-03-30
EP2146946A2 (en) 2010-01-27
IL201795A0 (en) 2010-06-16
PT2146946E (pt) 2011-02-14
CN101715437A (zh) 2010-05-26
CA2685570A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
ES2501592T3 (es) Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña
ES2491140T3 (es) Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
PE20131463A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
ECSP11011151A (es) Compuestos purina
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
DK2152651T3 (da) Terapeutiske forbindelser
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
SG10201806714PA (en) C7-fluoro substituted tetracycline compounds
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
EA200601845A1 (ru) НОВЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ
ECSP088781A (es) Derivados de benzimidazol
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
CO6511224A2 (es) Utilización de derivados del indol como activadores de nurr-1 para la aplicación de tratamientos de enfermedades como el parkison
ES2605454T3 (es) Métodos para reducir la neurodegeneración
EA200800125A1 (ru) Фармацевтическая композиция, включающая 1-(3-хлорфенил)-3-алкилпиперазин, для лечения расстройств аппетита
RU2009116125A (ru) Средство для предотвращения отека легких